Outcomes
The impact on the progression of
AR was measured by symptomatic AR medication prescription after expiry
of AIT treatment considering the probability of requiring symptomatic AR
medication in the follow-up period and the number and reduction of AR
prescriptions in the follow-up period standardized by year compared to
the pre-index period.
For asthmatic patients, defined as patients treated with two
prescriptions of an anti-asthmatic medication in the same or two
sub-sequent allergy seasons, the impact of the study products on the
progression of asthma was measured analogously. The other patients were
classified as non-asthmatic at baseline. After expiry of AIT treatment
the impact of the study products on the progression of asthma was
measured by the probability of requiring anti-asthmatic medication and
number and reduction of anti-asthmatic prescriptions in the follow-up
period standardized by year after AIT compared to the pre-index period.
For non-asthmatic patients at index date, the impact on asthma incidence
was measured analogously by the occurrence and by time to prescription
of anti-asthmatic medication in the follow-up period.